首页> 外文期刊>Clinical microbiology and infection: European Society of Clinical Microbiology and Infectious Diseases >Antifungal therapy for patients with proven or suspected Candida peritonitis: Amarcand2, a prospective cohort study in French intensive care units
【24h】

Antifungal therapy for patients with proven or suspected Candida peritonitis: Amarcand2, a prospective cohort study in French intensive care units

机译:患有经证实或疑似念珠菌腹膜炎的患者的抗真菌治疗:Amarcand2,法国重症监护单位前瞻性队列研究

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: The clinical characteristics and prognosis of patients treated for Candida peritonitis (CP) were compared according to the type of systemic antifungal therapy (SAT), empiric (EAF) or targeted (TAF) therapies, and the final diagnosis of infection.
机译:目的:根据系统性抗真菌疗法(SAT),经验(EAF)或靶向(TAF)疗法的临床特征和预后进行比较,以及靶向(TAF)疗法,以及对感染的最终诊断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号